Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol INVA
Innoviva
INVA
67
$15.91arrow_drop_down0.50%-$0.08

Performance History

Chart placeholder
Key Stats
Open$15.93
Prev. Close$15.99
EPS2.24
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$970.39M
PE Ratio7.10
LOWHIGH
Day Range15.74
15.95
52 Week Range12.22
16.86
Ratios
P/B Ratio1.37
Revenue$324.26M
Operating M. %33.30%
Earnings$179.72M
Earnings Growth %-18.41%
EBITDA Margin %54.07%
ROE %28.67%
EPS2.24

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Innoviva (INVA)

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Sector
Healthcare
Industry
Biotechnology
CEO
-
Headquarters
Burlingame
Employees
101
Exchange
NASDAQ
add Innoviva  to watchlist

Keep an eye on Innoviva

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the market capitalization of Innoviva (INVA)?

Innoviva (INVA) has a market capitalization of $970.39M. The average daily trading volume is 398.75K, indicating the stock's liquidity and investor engagement.

help
What is Innoviva 's (INVA) price per share?

The current price per share for Innoviva (INVA) is $15.91. The stock has seen a price change of -$0.08 recently, indicating a -0.5% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Innoviva (INVA)?

For Innoviva (INVA), the 52-week high is $16.86, which is 5.97% from the current price. The 52-week low is $12.22, the current price is 30.2% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Innoviva (INVA) a growth stock?

Innoviva (INVA) has shown an average price growth of 0.41% over the past three years. It has received a score of 77 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Innoviva as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Innoviva (INVA) stock price performance year to date (YTD)?

As of the latest data, Innoviva (INVA) has a year-to-date price change of -2.81%. Over the past month, the stock has experienced a price change of 0.44%. Over the last three months, the change has been 7.07%. Over the past six months, the figure is 2.71%. Looking at a longer horizon, the five-year price change stands at 11.81%.

help
Is Innoviva (INVA) a profitable company?

Innoviva (INVA) has a net income of $179.72M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.84% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 33.3% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $324.26M, although specific revenue growth data is currently not available. The gross profit is $245.92M. Operating income is noted at $113.88M. Furthermore, the EBITDA is $243.12M.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level